Trial Profile
MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biogen
- 03 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Aug 2018 Planned End Date changed from 30 Jun 2018 to 31 Oct 2018.
- 27 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Oct 2018.